We are excited to announce the CNS Diseases Summit, to be held on September 11-12, 2017 in Boston, MA. This meeting provides an interactive learning and relationship-building forum for all players in the CNS field. Colleagues from industry, academia, government agencies, and financing bodies will gather at the interface of research, partnerships, funding, and commercialization to find ways to move forward in a field that has been troubled with clinical failures.
The program will provide a comprehensive look at the current state of CNS, from research to commercialization. Above all, this event will provide networking opportunities in an intimate and accessible environment.
We invite you to join us as we connect, build relationships, and seek new ways forward into the future of CNS research and development.
Joint Plenary Sessions:
I. Opening Keynote Session – Historical Perspective & Current State of the Industry
II. Round Table Discussions: Neuroinflammation, Neuroimaging & Translational Biomarkers
III. Ready, Set, Grow – New Company/Technology Pitch Competition
IV. Award Ceremony & Closing Keynote Session – Predictions for future
11th Neurodegenerative Diseases Research & Development
I. Experimental Therapeutics & Approaches in Alzheimer’s Disease & Related Dementias
II. Advances in Parkinson’s Disease Research & Therapeutics
III. Next Frontier in Multiple Sclerosis to Limit or Reverse Neurodegeneration
IV. Therapeutics for Rare & Orphan CNS Disorders
10th CNS Partnering & Deal-making
I. What’s New in CNS – Targets, Models, Assays, etc.
II. Industry Partnering with Academia & CROs to Advance Research
III. CNS Perspectives from Venture Capital & Public Markets
IV. Technology Transfer & Licensing: Challenges & Opportunities
We hope to see you there!
The 2017 Advisory Committee
|2017 Advisory Board Members|
|Mark Allegretta, National Multiple Sclerosis Society|
|Patrick Brundin, Van Andel Research Institute|
|Roopali Gandhi, Harvard Medical School|
|Arti Gaur, Dartmouth Geisel School of Medicine|
|Linda Hedley, Hedley Consulting|
|Ole Isacson, Harvard Medical School|
|Satish Medicetty, GTCbio|
|Katrina Paumier, Michigan State University|
|Suzana Petanceska, National Institute on Aging, NIH|
|Robert Scannevin, Yumanity|
|Malu Tansey, Emory University|
|Harry Tracy, President, NI Research|
|Shafique Virani, BridgeBio|
|Cheryl Wellington, University of British Columbia|
|Iva Toudjarska, Halloran Consulting Group|
|Charles Duncan, Piper Jaffray & Co.|
|Christine Brennan, Novartis Venture Fund|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
SRI provides broad expertise in antiviral and vaccine efficacy /safety studies, utilizing its extensive collection of human and animal Influenza isolates, and providing: in vitro evaluation, customizable in vivo models, vaccine discovery /development, discovery tools in ferret model. SRI offers research, discovery /development CRO services, Phase I Clinical Trials.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.